Login to Your Account



Strong Phase II Resminostat Data Send 4SC Shooting Up

By Cormac Sheridan
BioWorld Today Correspondent

Friday, January 20, 2012
Shares in 4SC AG surged more than 38 percent Thursday on news that its histone deacetylase (HDAC) inhibitor resminostat hit the primary endpoint of a Phase II trial in advanced hepatocellular carcinoma (HCC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription